Encompass Health Corp
EHC- Exchange
- NYSE
- Industry
- Services-Hospitals
- SEC CIK
- 0000785161
In the last 90 days, Encompass Health Corp insiders filed 0 open-market purchases and 2 sales; 602 institutions reported holding it in 13F filings for Q2 2026, worth $9.63B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:07 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 5, 2026 | Feb 6, 2025 | Feb 7, 2024 | Feb 7, 2023 | Feb 1, 2022 |
| Revenue | $5.94B | $5.37B | $4.80B | $4.35B | $5.12B |
| Selling, general and administrative | $236.2M | $209.2M | $201.7M | $154.3M | $197.3M |
| Operating income | – | – | – | $539.5M | – |
| Interest expense | – | – | $143.5M | $175.7M | $164.6M |
| Income tax | $192.9M | $150.2M | $132.2M | $100.1M | $139.6M |
| Net income | $566.2M | $455.7M | $352.0M | $271.0M | $412.2M |
| EPS, basic | $5.62 | $4.53 | $3.51 | $2.72 | $4.15 |
| EPS, diluted | $5.54 | $4.46 | $3.47 | $2.70 | $4.11 |
| Weighted shares, basic | 100.5M | 99.9M | 99.5M | 99.2M | 99.0M |
| Weighted shares, diluted | 102.2M | 102.2M | 101.3M | 100.4M | 100.2M |
| Margins and growth | |||||
| Operating margin | – | – | – | 12.4% | – |
| Net margin | 9.5% | 8.5% | 7.3% | 6.2% | 8.0% |
| Revenue growth, year over year | +10.5% | +11.9% | +10.4% | −15.1% | +10.3% |
| Net income growth, year over year | +24.2% | +29.5% | +29.9% | −34.3% | +45.0% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 5, 2026 | Feb 6, 2025 | Feb 7, 2024 | Feb 7, 2023 | Feb 1, 2022 |
| Cash and equivalents | $72.2M | $85.4M | $69.1M | $21.8M | $54.8M |
| Accounts receivable | $613.4M | $593.0M | $599.8M | $524.8M | $666.6M |
| Total current assets | $905.9M | $886.9M | $841.8M | $717.2M | $921.4M |
| Goodwill | $1.32B | $1.28B | $1.28B | $1.26B | $2.43B |
| Intangible assets | $308.3M | $297.8M | $278.2M | $282.3M | $417.5M |
| Total assets | $7.09B | $6.53B | $6.10B | $5.64B | $6.86B |
| Accounts payable | $178.2M | $171.0M | $170.0M | $132.9M | $137.6M |
| Total current liabilities | $836.4M | $841.0M | $656.4M | $575.9M | $748.8M |
| Total liabilities | $3.81B | $3.69B | $3.81B | $3.77B | $4.47B |
| Shareholders' equity | $3.22B | $2.79B | $2.26B | $1.83B | $2.36B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 5, 2026 | Feb 6, 2025 | Feb 7, 2024 | Feb 7, 2023 | Feb 1, 2022 |
| Operating cash flow | – | – | – | $705.8M | $715.8M |
| Capital expenditures | $736.4M | $642.5M | $583.1M | $564.8M | $528.9M |
| Free cash flow | – | – | – | $141.0M | $186.9M |
| Depreciation and amortization | $327.9M | $299.6M | $273.9M | $243.6M | $256.6M |
| Stock-based compensation | $56.5M | $48.3M | $50.6M | $29.2M | $32.8M |
| Dividends paid | $71.1M | $62.8M | $60.4M | $99.0M | $112.4M |
| Share buybacks | $158.0M | $31.1M | – | $0 | $0 |
| Investing cash flow | -$764.6M | -$653.3M | -$602.8M | -$627.0M | -$666.3M |
| Financing cash flow | -$431.2M | -$330.6M | -$197.2M | -$145.7M | -$240.1M |
| Net change in cash | -$20.2M | $18.9M | $50.8M | -$66.9M | -$190.6M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 1.0% | 0.9% | 1.1% | 0.7% | 0.6% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 22, 2026 | 98.1M | −2.5% | SEC |
| Jul 28, 2026 | 98.7M | −2.1% | SEC |
| Apr 24, 2026 | 99.2M | −1.6% | SEC |
| Feb 12, 2026 | 99.4M | −1.3% | SEC |
| Oct 21, 2025 | 100.6M | −0.1% | SEC |
| Jul 28, 2025 | 100.7M | +0.1% | SEC |
| Apr 23, 2025 | 100.8M | +0.1% | SEC |
| Feb 13, 2025 | 100.7M | +0.6% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.